Presentation

0 Comments

3 January 2017

Combination sirolimus-eluting and anti-CD34 antibody-coated stent

Stephen Rowland

Industry presentation on the Combo dual therapy stent

Previous | Next
Download

Summary

Presentation on the design of Combo – a stent eluting Sirolimus from a biodegradable polymer matrix in combination with an anti-CD34 antibody coating on its luminal surface. CD34 is expressed by endothelial progenitor cells and thus the antibody functions to promote their capture and facilitate rapid endothelialisation of the stent. The results of REMEDEE, a first-in-man randomised study of Combo in comparison with a second generation Paclitaxel-eluting stent (TAXUS Liberte, Boston Scientific) in PCI for stable coronary artery disease are presented. At nine months follow-up, Combo demonstrates non-inferiority for the primary outcome, angiographic 9 month in-stent late loss, with a low overall event rate in both arms, including no stent thrombosis.

Download

Summary

Presentation on the design of Combo – a stent eluting Sirolimus from a biodegradable polymer matrix in combination with an anti-CD34 antibody coating on its luminal surface. CD34 is expressed by endothelial progenitor cells and thus the antibody functions to promote their capture and facilitate rapid endothelialisation of the stent. The results of REMEDEE, a first-in-man randomised study of Combo in comparison with a second generation Paclitaxel-eluting stent (TAXUS Liberte, Boston Scientific) in PCI for stable coronary artery disease are presented. At nine months follow-up, Combo demonstrates non-inferiority for the primary outcome, angiographic 9 month in-stent late loss, with a low overall event rate in both arms, including no stent thrombosis.

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In